Danaher Has Barely Moved in a Year. Is its 25x Earnings Valuation Justified?

Danaher Corporation (NYSE:DHR) has had little to show shareholders for the past year. The stock has surged by only a little over 4% in the past 12 months, compared with a nearly 16% return for the broader market.

That underperformance might make Danaher look inexpensive at first glance, but based on the midpoint of Danaher’s 2026 adjusted diluted net earnings per common share guidance of $8.45 to $8.60, the stock trades at approximately 25 times forward adjusted earnings.

Valuation thus raises an interesting question for investors, one which asks what justifies paying a premium multiple for Danaher despite its lackluster share-price performance, and whether the stock’s expected recovery is playing a role in this. But before we dive into the investment story, take a look at our recently published article on Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing? for better comparative insight.

The Recovery Is Starting to Show

Danaher’s recent operating performance provides some justification for that premium. In the second quarter, revenue increased 5.5% year over year to $6.3 billion, while driving high-single-digit adjusted EPS growth. More importantly for the longer-term valuation story, core revenue increased 3% year-over-year, and non-GAAP core revenue rose 4.5% year-over-year, excluding respiratory testing revenue. Danaher said its Life Sciences businesses delivered their strongest quarter in several years, while bioprocessing orders grew at a mid-teens rate.

That is significant for the stock’s investment story because it shows that the company is not just relying on cost-cutting as a means to support its earnings. Management expects continued end-market recovery and said it expects to exit 2026 at a mid-single-digit core revenue growth rate, supported by its growth initiatives. Full-year core revenue is currently expected to grow 3% to 4%.

There is also an acquisition component to the growth story, as Danaher completed its acquisition of Masimo in June for a business that provides pulse oximetry and patient-monitoring technologies. The company described Masimo as a strategic fit with its Diagnostics portfolio and said the combination should help accelerate Masimo’s growth and global reach. For more insight into the sector, there are nine healthcare stocks other than DHR in our ranking of the best healthcare stocks to buy according to hedge funds. Check out the complete list here.

But the Valuation Already Assumes a Recovery

At approximately 25 times 2026 adjusted earnings, the market is paying a significant premium to the company’s expected earnings growth. The company also expects only 3% to 4% core revenue growth for the full year. Diagnostics is expected to be roughly flat in the third quarter and only “up slightly” for the full year, while respiratory-testing revenue is still providing a low-single-digit boost to reported core growth.

In other words, Danaher Corporation (NYSE:DHR) is being valued as a business capable of returning to stronger growth, rather than simply on the growth it is producing today. Danaher has underperformed the S&P 500, yet investors are still paying about 25x forward adjusted earnings for a company guiding to only 3%–4% core revenue growth. The bull case therefore depends on whether the current recovery can accelerate beyond what the 2026 numbers currently show.

The Masimo Bet Adds Another Layer

The Masimo acquisition could help justify that premium if Danaher can accelerate the business and generate the expected synergies. But the price paid shows that Danaher itself was willing to make a substantial investment in future growth.

Danaher agreed to acquire Masimo for $180 per share in cash, representing an enterprise value of approximately $9.9 billion. The transaction was valued at roughly 18 times estimated 2027 EBITDA, or 15 times estimated 2027 EBITDA including the full benefit of expected annual synergies.

That is not an inexpensive acquisition, and it raises the stakes for Danaher’s capital-allocation strategy at a time when the broader business is still recovering. For more insight into how Danaher compares with investment stories for other popular healthcare stocks, take a look at our insightful article on Danaher vs. Medtronic: Which Healthcare Recovery Story Has More Upside?.

Is 25 Times Earnings Justified?

Danaher’s valuation is difficult to call cheap based on its current growth rate. The company is expecting mid-single-digit core revenue growth as it exits 2026. Against that backdrop, a 25x earnings multiple may be thought of as leaving limited room for operational disappointment.

The bullish argument is that the current numbers may understate Danaher’s longer-term potential. Bioprocessing orders are recovering, Life Sciences has improved, Masimo adds another diagnostics platform, and management expects the company’s core growth rate to accelerate as end markets recover.

The bearish argument paints a much simpler picture, which is that investors are already paying for much of that recovery. If Danaher remains stuck around low-single-digit core growth, a 25x multiple could prove difficult to sustain.

The Bottom Line

Danaher Corporation (NYSE:DHR) does not look expensive because its stock has performed well but rather looks expensive because investors are assigning a premium multiple to a recovery that is still underway.

At roughly 25 times 2026 adjusted earnings, the market is demanding more than Danaher’s current 3% to 4% core revenue growth. The improving bioprocessing business, stronger Life Sciences performance, and Masimo acquisition provide credible reasons to expect better growth ahead.

But that is precisely what the valuation already appears to anticipate. Danaher can justify its premium if the current recovery develops into sustained mid-single-digit or better growth. Otherwise, its relatively modest operating growth could make a 25x earnings multiple look difficult to defend.

READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth? 

This article is originally published at Insider Monkey.